New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 5mg;   - tablet - 5 mg - active: medroxyprogesterone acetate 5mg   excipient: calcium stearate indigo carmine lactose monohydrate liquid paraffin maize starch purified talc purified water sucrose - provera low dosage (2.5mg, 5mg and 10mg tablets) are indicated for: · diagnosis of primary and secondary amenorrhoea · treatment of dysfunctional (anovulatory) uterine bleeding · opposition of endometrial effects of estrogen in menopausal women being treated with estrogen (hormone replacement therapy [hrt]) · treatment of endometriosis.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 2.5mg;   - tablet - 2.5 mg - active: medroxyprogesterone acetate 2.5mg   excipient: calcium stearate lactose monohydrate liquid paraffin maize starch purified talc purified water sucrose sunset yellow fcf - provera low dosage (2.5mg, 5mg and 10mg tablets) are indicated for: · diagnosis of primary and secondary amenorrhoea · treatment of dysfunctional (anovulatory) uterine bleeding · opposition of endometrial effects of estrogen in menopausal women being treated with estrogen (hormone replacement therapy [hrt]) · treatment of endometriosis.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - medroxyprogesterone acetate - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sigma pharmaceuticals plc - medroxyprogesterone acetate - oral tablet - 5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

necessity supplies ltd - medroxyprogesterone acetate - oral tablet - 5mg

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: indigo carmine; maize starch; sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; purified talc; calcium stearate; liquid paraffin; maize starch; sunset yellow fcf; sucrose - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4.abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.

Canada - English - Health Canada

pfizer canada ulc - medroxyprogesterone acetate - tablet - 5mg - medroxyprogesterone acetate 5mg - progestins

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - medroxyprogesterone acetate - tablet - 5 milligram(s) - pregnen (4) derivatives; medroxyprogesterone

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 500 mg - tablet, uncoated - excipient ingredients: gelatin; sodium benzoate; purified water; docusate sodium; sodium starch glycollate; magnesium stearate; microcrystalline cellulose; maize starch; isopropyl alcohol; macrogol 400 - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.